

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-31. (canceled)

32. (currently amended) A method of preparing a composition or kit for filling or short-circuiting vascular cavities, comprising:

adding components to be delivered to a vascular cavity, said components consisting essentially of:

~~obtaining i)~~ a sufficient amount of polyurethane ~~so that said polyurethane is capable of filling or short-circuiting~~  
a to fill or short-circuit a vascular cavity, and

~~obtaining ii)~~ a sufficient amount of a solvent or a solvent mixture mingling with body fluids to dissolve said polyurethane, wherein,

said polyurethane is soluble in said solvent or solvent mixture so as to form a polyurethane solution mingling with body fluids so that said polyurethane can be dissolved in said solvent or solvent mixture mingling with body fluids, and said polyurethane solidifies upon separation of said solvent or solvent mixture from said solution,

said solvent or solvent mixture is usable in humans and animals and is discharged from said polyurethane once said polyurethane fills or short-circuits said vascular cavities, and said components do not stick to blood vessel walls.

~~adding said polyurethane and said solvent or solvent mixture mingling with body fluids to said composition or kit.~~

33. (currently amended) The method according to claim 32, wherein ~~[[the]]~~ said polyurethane is dissolved ~~in a~~ in said solvent or ~~[[a]]~~ solvent mixture mingling with body fluids in said adding step.

34. (currently amended) The method according to claim 32, wherein,

said adding step prepares a kit with ~~is manufactured~~ ~~and~~ said polyurethane and said solvent or solvent mixture mingling with body fluids present in separate subunits ~~are formulated separately~~ or in a common subunit.

35. (previously presented) The method according to claim 32, wherein said solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), C2-C4 alcohols, ethyl lactate, and dimethyl formamide.

36. (currently amended) The method according to claim 35, wherein ~~[[the]]~~ said solvent is DMSO or EtOH or a mixture thereof.

37. (currently amended) The method according to claim 32, wherein ~~[[the]]~~ said polyurethane comprises a main diol component characterized by the general formula of HO-R'-OH, where R' stands for a C1-C8 alkylene group.

38. (previously presented) The method according to claim 37, wherein 50 to 95 % of the main diol component is in polyether form.

39. (currently amended) The method according to claim 32, wherein ~~[[the]]~~ said polyurethane comprises a main diisocyanate component selected from the group consisting of 2,4- or 2,6-toluylene-diisocyanate (TDI), 1,6-hexane- diisocyanate and diphenyl-methane-4,4'-diisocyanate (MDI).

40. (currently amended) The method according to claim 32, wherein ~~[[the]]~~ said polyurethane is in a solution having a viscosity higher than 150 mPa.s at 23 °C.

41. (currently amended) The method according to claim

32, wherein ~~[[the]]~~ said polyurethane is in a solution having a viscosity lower than 1000 mPa.s at 23 °C.

42. (currently amended) The method according to claim 32, wherein the molecular mass of ~~[[the]]~~ said polyurethane is 4000 to 70000 Dalton.

43. (currently amended) The method according to claim 32, ~~wherein the composition or kit contains an~~ further comprising:

adding an auxiliary material for visually following said components during delivery to and filling or short circuiting of a vascular cavity, wherein,

said auxiliary is selected from the group consisting of a substance containing tantalum, a substance containing iodine, a substance containing barium, a substance containing tungsten, a substance containing bismuth and mixtures thereof.

44. (previously presented) The method according to claim 32, wherein said polyurethane is linear.

45. (currently amended) The method according to claim ~~[[32]]~~ 43, wherein said auxiliary material is selected from the group consisting of tantalum micronized powder, tantalum oxide,

barium sulphate, ethyl-10 (p-iodinephenyl) undecylate and tungsten.

46. (currently amended) A composition or kit for filling or short-circuiting vascular cavities, comprising:

components to be delivered to a vascular cavity, said components consisting essentially of:

i) a sufficient amount of polyurethane ~~so that said polyurethane is capable of filling or short-circuiting~~ to fill or short-circuit a vascular cavity, and

ii) a sufficient amount of solvent or a solvent mixture mingling with body fluids to dissolve said polyurethane, wherein,

said polyurethane is soluble in said solvent or solvent mixture so as to form a polyurethane solution ~~mingling with body fluids~~, and said polyurethane solidifies upon separation of said solvent or solvent mixture from said solution, and

said solvent or solvent mixture is usable in humans and animals and is discharged from said polyurethane once said polyurethane fills or short-circuits said vascular cavities, and

said components do not stick to blood vessel walls.

47. (currently amended) The composition or kit according to claim 46, wherein ~~[[the]]~~ said polyurethane is dissolved in ~~[[a]]~~ said solvent mixture mingling with body fluids.

48. (currently amended) The kit according to claim 46, wherein [[a]] said kit comprises components i) and ii) formulated separately or in a common subunit.

49. (previously presented) The composition or kit according to claim 46, wherein said solvent is selected from the group consisting of dimethyl sulfoxide (DMSO) , C2-C4 alcohols, ethyl lactate, and dimethyl formamide.

50. (currently amended) The composition or kit according to claim 49, wherein [[the]] said solvent is DMSO or EtOH or their mixture.

51. (previously presented) The composition or kit according to claim 46, wherein the main diol component of the polyurethane is characterized by the general formula of HO-R'-OH, where R' stands for a C1-C8 alkylene group.

52. (previously presented) The composition or kit according to 51, wherein 50 to 95 % of the main diol component is in polyether form.

53. (currently amended) The composition or kit according to claim 46, wherein [[the]] said polyurethane

comprises a main diisocyanate component selected from the group consisting of 2,4- or 2,6-toluylene-diisocyanate (TDI), 1,6-hexane- diisocyanate and diphenyl-methane-4,4'-diisocyanate (MDI).

54. (currently amended) The composition or kit according to claim 46, wherein [[the]] said polyurethane is in a solution having a viscosity higher than 150 mPa.s at 23 °C.

55. (currently amended) The composition or kit according to claim 46, wherein [[the]] said polyurethane is in a solution having a viscosity lower than 1000 mPa.s at 23 °C.

56. (previously presented) The composition or kit according to claim 46, wherein said polyurethane is linear.

57. (currently amended) The composition or kit according to claim 46, further comprising:

an auxiliary material for visually following said components during delivery to and filling or short circuiting of a vascular cavity,

wherein said auxiliary is selected from the group consisting of tantalum micronized powder, tantalum oxide, barium sulphate, ethyl-10 (p-iodinephenyl) undecylate, and tungsten.

58. (currently amended) The composition or kit according to claim 46, wherein [[a]] said kit further comprises a catheter.